Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.

<h4>Objective</h4>Impaired liver regeneration is associated with a poor outcome in patients with decompensated alcoholic liver disease (ALD). We assessed whether autologous bone marrow mononuclear cell transplantation (BMMCT) improved liver function in decompensated ALD.<h4>Design&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laurent Spahr, Yves Chalandon, Sylvain Terraz, Vincent Kindler, Laura Rubbia-Brandt, Jean-Louis Frossard, Romain Breguet, Nicolas Lanthier, Annarita Farina, Jakob Passweg, Christoph D Becker, Antoine Hadengue
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/0c0b1305d41a4679a7a3450c1a5ce16c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0c0b1305d41a4679a7a3450c1a5ce16c
record_format dspace
spelling oai:doaj.org-article:0c0b1305d41a4679a7a3450c1a5ce16c2021-11-18T08:01:37ZAutologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.1932-620310.1371/journal.pone.0053719https://doaj.org/article/0c0b1305d41a4679a7a3450c1a5ce16c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23341981/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Impaired liver regeneration is associated with a poor outcome in patients with decompensated alcoholic liver disease (ALD). We assessed whether autologous bone marrow mononuclear cell transplantation (BMMCT) improved liver function in decompensated ALD.<h4>Design</h4>58 patients (mean age 54 yrs; mean MELD score 19, all with cirrhosis, 81% with alcoholic steatohepatitis at baseline liver biopsy) were randomized early after hospital admission to standard medical therapy (SMT) alone (n = 30), including steroids in patients with a Maddrey's score ≥32, or combined with G-CSF injections and autologous BMMCT into the hepatic artery (n = 28). Bone marrow cells were harvested, isolated and reinfused the same day. The primary endpoint was a ≥3 points decrease in the MELD score at 3 months, corresponding to a clinically relevant improvement in liver function. Liver biopsy was repeated at week 4 to assess changes in Ki67+/CK7+ hepatic progenitor cells (HPC) compartment.<h4>Results</h4>Both study groups were comparable at baseline. After 3 months, 2 and 4 patients died in the BMMCT and SMT groups, respectively. Adverse events were equally distributed between groups. Moderate alcohol relapse occurred in 31% of patients. The MELD score improved in parallel in both groups during follow-up with 18 patients (64%) from the BMMCT group and 18 patients (53%) from the SMT group reaching the primary endpoint (p = 0.43 (OR 1.6, CI 0.49-5.4) in an intention to treat analysis. Comparing liver biopsy at 4 weeks to baseline, steatosis improved (p<0.001), and proliferating HPC tended to decrease in both groups (-35 and -33%, respectively).<h4>Conclusion</h4>Autologous BMMCT, compared to SMT is a safe procedure but did not result in an expanded HPC compartment or improved liver function. These data suggest either insufficient regenerative stimulation after BMMCT or resistance to liver regenerative drive in patients with decompensated alcoholic cirrhosis.<h4>Trial registration</h4>Controlled-Trials.com ISRCTN83972743.Laurent SpahrYves ChalandonSylvain TerrazVincent KindlerLaura Rubbia-BrandtJean-Louis FrossardRomain BreguetNicolas LanthierAnnarita FarinaJakob PasswegChristoph D BeckerAntoine HadenguePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e53719 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Laurent Spahr
Yves Chalandon
Sylvain Terraz
Vincent Kindler
Laura Rubbia-Brandt
Jean-Louis Frossard
Romain Breguet
Nicolas Lanthier
Annarita Farina
Jakob Passweg
Christoph D Becker
Antoine Hadengue
Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
description <h4>Objective</h4>Impaired liver regeneration is associated with a poor outcome in patients with decompensated alcoholic liver disease (ALD). We assessed whether autologous bone marrow mononuclear cell transplantation (BMMCT) improved liver function in decompensated ALD.<h4>Design</h4>58 patients (mean age 54 yrs; mean MELD score 19, all with cirrhosis, 81% with alcoholic steatohepatitis at baseline liver biopsy) were randomized early after hospital admission to standard medical therapy (SMT) alone (n = 30), including steroids in patients with a Maddrey's score ≥32, or combined with G-CSF injections and autologous BMMCT into the hepatic artery (n = 28). Bone marrow cells were harvested, isolated and reinfused the same day. The primary endpoint was a ≥3 points decrease in the MELD score at 3 months, corresponding to a clinically relevant improvement in liver function. Liver biopsy was repeated at week 4 to assess changes in Ki67+/CK7+ hepatic progenitor cells (HPC) compartment.<h4>Results</h4>Both study groups were comparable at baseline. After 3 months, 2 and 4 patients died in the BMMCT and SMT groups, respectively. Adverse events were equally distributed between groups. Moderate alcohol relapse occurred in 31% of patients. The MELD score improved in parallel in both groups during follow-up with 18 patients (64%) from the BMMCT group and 18 patients (53%) from the SMT group reaching the primary endpoint (p = 0.43 (OR 1.6, CI 0.49-5.4) in an intention to treat analysis. Comparing liver biopsy at 4 weeks to baseline, steatosis improved (p<0.001), and proliferating HPC tended to decrease in both groups (-35 and -33%, respectively).<h4>Conclusion</h4>Autologous BMMCT, compared to SMT is a safe procedure but did not result in an expanded HPC compartment or improved liver function. These data suggest either insufficient regenerative stimulation after BMMCT or resistance to liver regenerative drive in patients with decompensated alcoholic cirrhosis.<h4>Trial registration</h4>Controlled-Trials.com ISRCTN83972743.
format article
author Laurent Spahr
Yves Chalandon
Sylvain Terraz
Vincent Kindler
Laura Rubbia-Brandt
Jean-Louis Frossard
Romain Breguet
Nicolas Lanthier
Annarita Farina
Jakob Passweg
Christoph D Becker
Antoine Hadengue
author_facet Laurent Spahr
Yves Chalandon
Sylvain Terraz
Vincent Kindler
Laura Rubbia-Brandt
Jean-Louis Frossard
Romain Breguet
Nicolas Lanthier
Annarita Farina
Jakob Passweg
Christoph D Becker
Antoine Hadengue
author_sort Laurent Spahr
title Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
title_short Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
title_full Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
title_fullStr Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
title_full_unstemmed Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
title_sort autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/0c0b1305d41a4679a7a3450c1a5ce16c
work_keys_str_mv AT laurentspahr autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT yveschalandon autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT sylvainterraz autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT vincentkindler autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT laurarubbiabrandt autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT jeanlouisfrossard autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT romainbreguet autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT nicolaslanthier autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT annaritafarina autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT jakobpassweg autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT christophdbecker autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
AT antoinehadengue autologousbonemarrowmononuclearcelltransplantationinpatientswithdecompensatedalcoholicliverdiseasearandomizedcontrolledtrial
_version_ 1718422587285962752